vs
Side-by-side financial comparison of Employers Holdings, Inc. (EIG) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Employers Holdings, Inc. is the larger business by last-quarter revenue ($170.5M vs $86.8M, roughly 2.0× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -21.3%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -11.4%).
Employers Holdings, Inc. is a U.S.-headquartered insurance holding company that specializes in offering workers' compensation insurance and customized risk management services primarily for small and medium-sized enterprises across the United States. It mainly serves clients in low-to-medium hazard industries, helping them mitigate workplace safety risks and meet relevant regulatory requirements for employee protection.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
EIG vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.5M | $86.8M |
| Net Profit | — | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | — | — |
| Revenue YoY | -21.3% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $170.5M | — | ||
| Q4 25 | $188.5M | $86.8M | ||
| Q3 25 | $239.3M | $67.5M | ||
| Q2 25 | $246.3M | $60.0M | ||
| Q1 25 | $202.6M | $49.3M | ||
| Q4 24 | $216.6M | $73.7M | ||
| Q3 24 | $224.0M | $58.6M | ||
| Q2 24 | $217.0M | $31.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-8.3M | $-91.3M | ||
| Q2 25 | $29.7M | $-111.7M | ||
| Q1 25 | $12.8M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $30.3M | $-83.5M | ||
| Q2 24 | $31.7M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | -84.7% | ||
| Q3 25 | -4.7% | -140.7% | ||
| Q2 25 | 15.0% | -189.8% | ||
| Q1 25 | 7.8% | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | 16.4% | -152.1% | ||
| Q2 24 | 18.4% | -327.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -3.5% | -135.3% | ||
| Q2 25 | 12.1% | -186.2% | ||
| Q1 25 | 6.3% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.5% | -142.7% | ||
| Q2 24 | 14.6% | -312.2% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.93 | — | ||
| Q3 25 | $-0.36 | — | ||
| Q2 25 | $1.23 | $-0.33 | ||
| Q1 25 | $0.52 | $-0.36 | ||
| Q4 24 | $1.14 | $-0.24 | ||
| Q3 24 | $1.21 | $-0.28 | ||
| Q2 24 | $1.25 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.9M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $955.7M | $698.6M |
| Total Assets | $3.4B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $169.9M | — | ||
| Q4 25 | $169.9M | $297.0M | ||
| Q3 25 | $172.4M | $300.8M | ||
| Q2 25 | $78.1M | $301.2M | ||
| Q1 25 | $100.4M | $359.7M | ||
| Q4 24 | $68.4M | $323.8M | ||
| Q3 24 | $173.9M | $397.5M | ||
| Q2 24 | $126.4M | $412.5M |
| Q1 26 | — | — | ||
| Q4 25 | $19.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $955.7M | — | ||
| Q4 25 | $955.7M | $698.6M | ||
| Q3 25 | $1.0B | $702.3M | ||
| Q2 25 | $1.1B | $698.5M | ||
| Q1 25 | $1.1B | $767.9M | ||
| Q4 24 | $1.1B | $710.4M | ||
| Q3 24 | $1.1B | $773.5M | ||
| Q2 24 | $1.0B | $768.5M |
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.4B | $913.2M | ||
| Q3 25 | $3.5B | $904.9M | ||
| Q2 25 | $3.5B | $907.4M | ||
| Q1 25 | $3.6B | $966.7M | ||
| Q4 24 | $3.5B | $910.4M | ||
| Q3 24 | $3.6B | $991.1M | ||
| Q2 24 | $3.5B | $964.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $44.7M | $-52.6M | ||
| Q3 25 | $29.4M | $-78.7M | ||
| Q2 25 | $0 | $-67.4M | ||
| Q1 25 | $14.6M | $-103.7M | ||
| Q4 24 | $76.4M | $-73.3M | ||
| Q3 24 | $51.0M | $-59.0M | ||
| Q2 24 | $11.7M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $44.6M | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | $76.3M | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | 35.2% | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 0.0% | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EIG
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
